Dal Forno G, Carson K A, Brookmeyer R, Troncoso J, Kawas C H, Brandt J
Department of Neurology, Neuropathology Laboratory, and the Alzheimer's Disease Research Center, The Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Neurology. 2002 Apr 9;58(7):1045-50. doi: 10.1212/wnl.58.7.1045.
The epsilon 4 allele of the APOE gene (APOE) is more frequent in patients with AD than in the general population, but studies are inconclusive as to whether it affects rate of progression or survival. Because survival in AD is generally longer in women than in men, the authors investigated whether APOE affects 10-year survival equally in men and women.
APOE testing was performed on 125 patients with probable AD enrolled in the Johns Hopkins AD Research Center between November 1984 and March 1987. The 39 men and 86 women were followed at 6-month intervals until censoring (by death or withdrawal from the study) or March 1997. Patients were dichotomized into those with and those without at least one epsilon 4 allele. For each sex, a Cox proportional hazards regression, allowing for delayed entry and covarying for age at onset, was used to examine the effect of epsilon 4 on survival.
All patients who died during the study period and had autopsy (n = 92) were found to have definite AD. Average survival from disease onset did not differ by sex (12.1 years in men; 12.3 years in women). In neither sex were differences found between epsilon 4-positive and epsilon 4-negative subgroups in education, duration of AD at entry, or severity of dementia. However, in both sexes the epsilon 4-positive subgroup was approximately 3 years older at onset of AD and at entry to the study than the epsilon 4-negative subgroup. Adjusting for age at onset, the presence of an epsilon 4 allele significantly increased the relative risk of death only for men (RR = 2.69; 95% CI = 1.23 to 5.87).
In this sample of mostly white, well-educated research participants with AD, the APOE epsilon 4 allele was associated with shorter survival in men but not in women.
载脂蛋白E基因(APOE)的ε4等位基因在阿尔茨海默病(AD)患者中比在普通人群中更常见,但关于它是否影响疾病进展速度或生存期,研究尚无定论。由于AD患者中女性的生存期通常比男性长,作者调查了APOE是否对男性和女性的10年生存期有同等影响。
对1984年11月至1987年3月在约翰霍普金斯AD研究中心登记的125例可能患有AD的患者进行APOE检测。39名男性和86名女性每6个月随访一次,直至截尾(因死亡或退出研究)或1997年3月。患者被分为至少有一个ε4等位基因和没有该等位基因的两组。对于每种性别,采用Cox比例风险回归模型,考虑延迟入组并对发病年龄进行协变量调整,以研究ε4对生存期的影响。
在研究期间死亡且接受尸检的所有患者(n = 92)均被确诊为AD。从疾病发作开始计算的平均生存期在性别上无差异(男性为12.1年;女性为12.3年)。在ε4阳性和ε4阴性亚组中,无论男性还是女性,在教育程度、入组时AD病程或痴呆严重程度方面均未发现差异。然而,在男性和女性中,ε4阳性亚组在AD发病时和进入研究时的年龄均比ε4阴性亚组大约大3岁。调整发病年龄后,ε4等位基因的存在仅显著增加了男性的相对死亡风险(RR = 2.69;95%CI = 1.23至5.87)。
在这个以白人为主、受过良好教育的AD研究参与者样本中,APOE ε4等位基因与男性生存期缩短有关,而与女性无关。